Strategic Blueprint LLC Makes New $244,000 Investment in IDEXX Laboratories, Inc. $IDXX

Strategic Blueprint LLC bought a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 455 shares of the company’s stock, valued at approximately $244,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in IDXX. MorganRosel Wealth Management LLC bought a new position in IDEXX Laboratories during the first quarter worth about $26,000. Opal Wealth Advisors LLC bought a new position in IDEXX Laboratories during the second quarter worth about $29,000. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in IDEXX Laboratories by 55.6% during the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock worth $35,000 after buying an additional 30 shares during the last quarter. Ameritas Advisory Services LLC bought a new position in IDEXX Laboratories during the second quarter worth about $36,000. Finally, WPG Advisers LLC bought a new position in IDEXX Laboratories during the first quarter worth about $37,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 1.0%

Shares of IDEXX Laboratories stock opened at $647.40 on Tuesday. The business’s 50 day simple moving average is $638.60 and its 200 day simple moving average is $562.04. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $688.12. The firm has a market cap of $51.79 billion, a PE ratio of 53.91, a P/E/G ratio of 4.15 and a beta of 1.58. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.28 by $0.35. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.IDEXX Laboratories’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter last year, the firm earned $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Insider Activity

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 29,260 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $631.98, for a total transaction of $18,491,734.80. Following the transaction, the chief executive officer owned 83,311 shares of the company’s stock, valued at $52,650,885.78. The trade was a 25.99% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director M Anne Szostak sold 2,187 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total value of $1,415,710.71. Following the transaction, the director directly owned 262 shares in the company, valued at $169,600.46. This trade represents a 89.30% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 54,057 shares of company stock worth $34,293,468. Corporate insiders own 0.98% of the company’s stock.

Analyst Ratings Changes

IDXX has been the topic of several recent analyst reports. JPMorgan Chase & Co. lifted their price objective on IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a report on Monday, August 4th. Stifel Nicolaus set a $640.00 price objective on IDEXX Laboratories in a report on Monday, August 4th. Morgan Stanley lifted their price objective on IDEXX Laboratories from $722.00 to $765.00 and gave the company an “overweight” rating in a report on Friday, August 15th. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Sunday, September 28th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of IDEXX Laboratories in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $656.50.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.